Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Potomac Health News.
Press releases published on June 26, 2025
Canada’s Bold Step Toward Becoming An Energy Super Power: Krishnan Suthanthiran’s Vision for a Sustainable Energy Future
EIN Presswire
·
June 26, 2025
WASHINGTON, DC, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- In a pivotal moment for Canada’s future, the nation is making strides to reduce its reliance on the United States for energy exports and elevate its role on the global stage. Krishnan …
Community Oncology Alliance Responds to Draft Guidance for Medicare Drug Price Negotiations
EIN Presswire
·
June 26, 2025
COA Responds to CMS Draft Guidance with Urgent Call for Action to Prevent Practice Closures and Protect Patient Access WASHINGTON, DC, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- The Community Oncology Alliance (COA) has submitted comprehensive …
A victory for scientists: NIH halts new grant terminations
EIN Presswire
·
June 26, 2025
Yesterday, the National Institutes of Health (NIH) have halted further terminations of grants: a key request from NIH scientists in the Bethesda Declaration. WASHINGTON, DC, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- This week before congress, …
PROJECT CURE CRC CONTINUES TO FUEL URGENTLY NEEDED RESEARCH FUNDING
EIN Presswire
·
June 26, 2025
The Colorectal Cancer Alliance Initiative is Bridging Gaps in Cancer Care Progress with Grants Totaling Almost $12 Million WASHINGTON, DC, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Project Cure CRC, the dynamic research initiative by the …
Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million
GlobeNewswire
·
June 26, 2025
Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, …
Extendicare Announces Renewal of Normal Course Issuer Bid
GlobeNewswire
·
June 26, 2025
MARKHAM, Ontario, June 26, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that the Toronto Stock Exchange (the “TSX”) has approved the renewal of Extendicare’s normal course issuer bid (“NCIB”). Under …
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
·
June 26, 2025
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its …
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
GlobeNewswire
·
June 26, 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that today it has completed its previously …
Teva Releases Q2 2025 Aide Memoire
GlobeNewswire
·
June 26, 2025
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website. Q2 2025 Aide Memoire Teva has prepared this …
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
GlobeNewswire
·
June 26, 2025
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ …
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
GlobeNewswire
·
June 26, 2025
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders …
Lifeward Announces Closing of $2.6 Million Public Offering
GlobeNewswire
·
June 26, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
GlobeNewswire
·
June 26, 2025
Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company’s initial public offering, has granted its …
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
GlobeNewswire
·
June 26, 2025
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. …
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
GlobeNewswire
·
June 26, 2025
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch …
Achieve Life Sciences Announces Proposed Underwritten Public Offering
GlobeNewswire
·
June 26, 2025
SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
GlobeNewswire
·
June 26, 2025
Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical …
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
GlobeNewswire
·
June 26, 2025
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More …
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
GlobeNewswire
·
June 26, 2025
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a …
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 26, 2025
VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …